Modality
Nanobody
MOA
WRNi
Target
MDM2
Pathway
Checkpoint
Heart FailureCRCMyelofibrosis
Development Pipeline
Preclinical
May 2023
→ Jun 2026
PreclinicalCurrent
NCT08244793
2,351 pts·CRC
2025-10→TBD·Not yet recruiting
NCT04314433
2,057 pts·Myelofibrosis
2023-05→2026-06·Not yet recruiting
4,408 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-062mo awayInterim· Myelofibrosis
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Preclinical
Not yet…
Preclinical
Not yet…
Catalysts
Interim
2026-06-06 · 2mo away
Myelofibrosis
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08244793 | Preclinical | CRC | Not yet recr... | 2351 | DOR |
| NCT04314433 | Preclinical | Myelofibrosis | Not yet recr... | 2057 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |